Featured Research

from universities, journals, and other organizations

Hormone therapy use by postmenopausal women may increase incidence of more advanced breast cancer

Date:
October 20, 2010
Source:
JAMA and Archives Journals
Summary:
Follow-up of about 11 years of participants in the Women's Health Initiative finds that among postmenopausal women, use of estrogen plus progestin is associated with an increased incidence of breast cancers that are more advanced, and with a higher risk of deaths attributable to breast cancer, according to a new study.

Follow-up of about 11 years of participants in the Women's Health Initiative finds that among postmenopausal women, use of estrogen plus progestin is associated with an increased incidence of breast cancers that are more advanced, and with a higher risk of deaths attributable to breast cancer, according to a study in the October 20 issue of JAMA.

In the Women's Health Initiative (WHI) randomized, placebo-controlled trial of estrogen plus progestin, after an average intervention time of 5.6 years and an average follow-up of 7.9 years, breast cancer incidence was increased among women who received combined hormone therapy. "… questions of clinical relevance remain, including the cumulative, long-term effect of estrogen plus progestin on breast cancer incidence and whether breast cancer mortality is increased by combined hormone therapy use," the authors write.

Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, Calif., and colleagues analyzed data and report updated information on breast cancer incidence and, for the first time, information on breast cancer mortality related to combined hormone therapy use in the WHI trial. A total of 16,608 postmenopausal women ages 50 to 79 years with no prior hysterectomy from 40 U.S. clinical centers were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill. After the original trial completion date (March 31, 2005), re-consent was required for continued follow-up for breast cancer incidence and was obtained from 12,788 (83 percent) of the surviving participants.

The researchers found that in intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up, estrogen plus progestin compared with placebo increased the incidence of invasive breast cancer (385 cases [0.42 percent per year] vs. 293 cases [0.34 percent per year], respectively). A significantly larger fraction of women in the combined hormone therapy group had breast cancers with positive lymph nodes compared with women in the placebo group (81 [23.7 percent] vs. 43 [16.2 percent], respectively).

"More women died of breast cancer in the combined hormone therapy group compared with the placebo group (25 deaths [0.03 percent per year] vs. 12 deaths [0.01 percent per year]), representing 2.6 vs. 1.3 deaths per 10,000 women per year, respectively," the authors write. "Consideration of all-cause mortality after breast cancer diagnosis provided similar results; among women in the combined hormone therapy group, there were 51 deaths (0.05 percent per year) compared with 31 deaths (0.03 percent per year) among women in the placebo group, representing 5.3 vs. 3.4 deaths per 10,000 women per year, respectively."

"With some exceptions, the preponderance of observational studies have associated combined hormone therapy use with an increase in breast cancers that have favorable characteristics, lower stage, and longer survival compared with breast cancers diagnosed in nonusers of hormone therapy. However, in the WHI randomized trial, combined hormone therapy increased breast cancer risk and interfered with breast cancer detection, leading to cancers being diagnosed at more advanced stages. Now, with longer follow-up results available, there remains a cumulative, statistically significant increase in breast cancers in the combined hormone therapy group, and the cancers more commonly had lymph node involvement. The observed adverse influence on breast cancer mortality of combined hormone therapy can reasonably be explained by the influence on breast cancer incidence and stage."

"Following the initial report of results from the WHI trial, a substantial decrease in breast cancer incidence occurred in the United States, which was attributed to the marked decrease in postmenopausal hormone therapy use that occurred after publication of the trial results. The adverse influence of estrogen plus progestin on breast cancer mortality suggests that a future reduction in breast cancer mortality in the United States may be anticipated as well," the researchers note.

Editorial: Postmenopausal Hormone Therapy and Breast Cancer -- An Uncertain Trade-off

In an accompanying editorial, Peter B. Bach, M.D., M.A.P.P., of Memorial Sloan-Kettering Cancer Center, New York, comments on the findings of Chlebowski and colleagues.

"… the available data dictate caution in the current approach to use of hormone therapy, particularly because one of the lessons from the WHI is that physicians are ill-equipped to anticipate the effect of hormone therapy on long-term health. Clinicians who prescribe brief courses of hormone therapy for relief of menopausal symptoms should be aware that this approach has not been proven in rigorous clinical trials and that the downstream negative consequences for their patients are of uncertain magnitude. One option -- discussing with patients the risk-benefit tradeoffs in pursuit of an informed patient decision -- may seem at first blush to be a reasonable approach given this lack of evidence. But the reality is that informed patient decisions are not valid when the information underlying the decision is itself speculative."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. Rowan T. Chlebowski; Garnet L. Anderson; Margery Gass; Dorothy S. Lane; Aaron K. Aragaki; Lewis H. Kuller; JoAnn E. Manson; Marcia L. Stefanick; Judith Ockene; Gloria E. Sarto; Karen C. Johnson; Jean Wactawski-Wende; Peter M. Ravdin; Robert Schenken; Susan L. Hendrix; Aleksandar Rajkovic; Thomas E. Rohan; Shagufta Yasmeen; Ross L. Prentice; for the WHI Investigators. Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. JAMA, 2010; 304 (15): 1684-1692 DOI: 10.1001/jama.2010.1500
  2. Peter B. Bach. Postmenopausal Hormone Therapy and Breast Cancer: An Uncertain Trade-off. JAMA, 2010; 304 (15): 1719-1720 DOI: 10.1001/jama.2010.1528

Cite This Page:

JAMA and Archives Journals. "Hormone therapy use by postmenopausal women may increase incidence of more advanced breast cancer." ScienceDaily. ScienceDaily, 20 October 2010. <www.sciencedaily.com/releases/2010/10/101019162201.htm>.
JAMA and Archives Journals. (2010, October 20). Hormone therapy use by postmenopausal women may increase incidence of more advanced breast cancer. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2010/10/101019162201.htm
JAMA and Archives Journals. "Hormone therapy use by postmenopausal women may increase incidence of more advanced breast cancer." ScienceDaily. www.sciencedaily.com/releases/2010/10/101019162201.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins